Evidence map›Paper›PMID 20386701›Full record

ArticlePloS one2010

Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications.

Sarah E Kelly, Altomare Di Benedetto, Adelaide Greco, Candace M Howard, Vincent E Sollars, Donald A Primerano, Jagan V Valluri, Pier Paolo Claudio

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.HSOA journal of stem cells research, development & therapy · 2021
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sarah E KellyDepartment of Biochemistry and Microbiology, Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, United States of America.
Altomare Di Benedetto
Adelaide Greco
Candace M Howard
Vincent E Sollars
Donald A Primerano
Jagan V Valluri
Pier Paolo Claudio
Marshall University · USCeinge Biotecnologie Avanzate (Italy) · IT

Funding

WVU &MU NEW FACULTY GRANTSP20RR016477 · NCRR · MARSHALL UNIVERSITY · PI REASOR, MARK J · 2001 to 2011
$35.5M
Transcription Factors in CancerP20RR020180 · NCRR · MARSHALL UNIVERSITY · PI NILES, RICHARD M. · 2004 to 2009
$9.5M
Ultrasound-guided gene delivery in pancreatic cancerR03CA140024 · NCI · MARSHALL UNIVERSITY · PI CLAUDIO, PIER PAOLO · 2009 to 2010
$142k
NCI NIH HHS CA138510NCI NIH HHS CA140024NCI NIH HHS R03 CA140024NCRR NIH HHS 5P20RR016477NCRR NIH HHS 5P20RR020180NCRR NIH HHS P20 RR016477NCRR NIH HHS P20 RR020180
6 · The paper itself

Abstract

Cancer stem cells (CSCs) are considered a subset of the bulk tumor responsible for initiating and maintaining the disease. Several surface cellular markers have been recently used to identify CSCs. Among those is CD133, which is expressed by hematopoietic progenitor cells as well as embryonic stem cells and various cancers. We have recently isolated and cultured CD133 positive [CD133+] cells from various cancer cell lines using a NASA developed Hydrodynamic Focusing Bioreactor (HFB) (Celdyne, Houston, TX). For comparison, another bioreactor, the rotary cell culture system (RCCS) manufactured by Synthecon (Houston, TX) was used. Both the HFB and the RCCS bioreactors simulate aspects of hypogravity. In our study, the HFB increased CD133+ cell growth from various cell lines compared to the RCCS vessel and to normal gravity control. We observed a +15-fold proliferation of the CD133+ cellular fraction with cancer cells that were cultured for 7-days at optimized conditions. The RCCS vessel instead yielded a (-)4.8-fold decrease in the CD133+cellular fraction respect to the HFB after 7-days of culture. Interestingly, we also found that the hypogravity environment of the HFB greatly sensitized the CD133+ cancer cells, which are normally resistant to chemo treatment, to become susceptible to various chemotherapeutic agents, paving the way to less toxic and more effective chemotherapeutic treatment in patients. To be able to test the efficacy of cytotoxic agents in vitro prior to their use in clinical setting on cancer cells as well as on cancer stem cells may pave the way to more effective chemotherapeutic strategies in patients. This could be an important advancement in the therapeutic options of oncologic patients, allowing for more targeted and personalized chemotherapy regimens as well as for higher response rates.

Indexed as

Antigens, CDCell ProliferationGlycoproteinsPeptidesAC133 AntigenAntineoplastic AgentsBioreactorsCell Line, TumorCell SeparationDrug Screening Assays, AntitumorHumansHypogravityNeoplastic Stem CellsAC133 AntigenAntigens, CDAntineoplastic AgentsGlycoproteinsPeptidesPROM1 protein, human

Identifiers

PMID20386701
PMCPMC2851647
OpenAlexW2017598664

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.